Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.38 |
| ▸ | IL1B | P01584 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30309032 | 0.91 | P2RX7 (0.40) | P2RX7IL1BLMNAADORA2AADORA2B | |
| SCHEMBL29195769 | 0.91 | P2RX7 (0.39) | P2RX7LMNAADORA2AADORA2BALDH1A1 | |
| SCHEMBL30309013 | 0.90 | LMNA (0.38) | LMNAADORA2AADORA2BALDH1A1KMT2A | |
| SCHEMBL29195800 | 0.89 | P2RX7 (0.40) | P2RX7LMNAADORA2AADORA2BALDH1A1 | |
| SCHEMBL29195848 | 0.88 | P2RX7 (0.41) | P2RX7LMNAADORA2AADORA2BALDH1A1 | |
| SCHEMBL29195783 | 0.87 | TP53 (0.42) | P2RX7LMNAADORA2AADORA2BALDH1A1 | |
| SCHEMBL31272332 | 0.86 | ALDH1A1 (0.39) | P2RX7IL1BLMNAALDH1A1KMT2A | |
| SCHEMBL29195801 | 0.86 | ADORA2A (0.38) | P2RX7LMNAADORA2AADORA2BALDH1A1 | |
| SCHEMBL30309012 | 0.86 | P2RX7 (0.45) | P2RX7IL1B | |
| SCHEMBL29195810 | 0.85 | P2RX7 (0.44) | P2RX7LMNAADORA2AADORA2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368092-A1 | 2,4-Dihydro-3H-1,2,4-Triazol-3-One P2X7 Antagonists | BREYE THERAPEUTICS APS (DK) | 2024-11-07 | — | — | US | disclosed |
| EP-4396181-A1 | 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE P2X7 ANTAGONISTS | Breye Therapeutics ApS (DK) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023031319-A1 | 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE P2X7 ANTAGONISTS | AXXAM S.P.A. (IT) | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368092-A1 | 2,4-Dihydro-3H-1,2,4-Triazol-3-One P2X7 Antagonists | P2RX3, P2RX7, P2RX2 | P2RX7 2/4885IL1B 115/4885LMNA 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.